Latest Intellectual Property News

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

ION Video has entered substantive early-stage discussions with Meta and Alphabet, exploring potential applications of its patented video virtualization technology. These talks are part of a broader engagement with major global tech players, though no formal deals have yet been struck.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Argent BioPharma has finalized the acquisition of CannPal Animal Therapeutics, securing a Phase 3 veterinary epilepsy asset with near-term commercial prospects and an option to acquire the Neuvis® drug delivery platform, enhancing its neurological portfolio and U.S. market ambitions.

WhiteHawk (ASX: WHK) has acquired Quixxi, gaining the Clarity AI platform to extend its cybersecurity services into the burgeoning global AI governance sector. The deal positions WhiteHawk at the convergence of cybersecurity, data governance, and AI risk management amid rapid market growth and regulatory momentum.

Metallium Limited has marked a pivotal quarter with over 40 Flash Joule Heating campaigns completed and a strategic capital raise boosting cash reserves to A$82 million. The company is gearing up for multi-reactor operation at its Texas campus, underpinned by long-term agreements with Indium Corporation and Glencore.

Ainsworth Game Technology Limited has released its Target’s Statement recommending shareholders accept an unconditional proportional off-market takeover bid by Mr Kjerulf David Hastings Ainsworth at $1.30 per share, representing a premium to recent trading prices.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.

Marquee Resources has entered a 24-month patent license and option agreement with UT-Battelle LLC, granting access to advanced rare earth element separation technologies from Oak Ridge National Laboratory. This positions Marquee to explore downstream processing opportunities for its Redlings REE Project in Western Australia.

Zinc of Ireland NL (ASX: ZMI) has entered a binding agreement to acquire Dutch metals technology company Meclex, integrating proprietary hydrometallurgical processes ARGO and VOLTA with its Kildare Zinc project. The company also announced a $5.5 million placement to support exploration and technology development alongside new board appointments.

Wide Open Agriculture Ltd (ASX: WOA) has received a A$1,686,579 R&D tax rebate for the 2024-25 financial year, reflecting its significant innovation efforts in lupin protein development across Australia and Germany. The rebate will support the company’s commercialisation and growth initiatives.